AFP and hepatocellular carcinoma: Shaker et al. investigated the clinical utility of ANXA2 serum levels as a novel diagnostic marker of HCC in Egyptian patients, suggesting that ANXA2 might be a good biomarker for the early detection of HCC for the higher sensitivity, specificity, and positive and negative predictive values compared to that of alpha-fetoprotein (AFP) [106].